natgillin/translations-raw huggingface dataset:
What is Onduarp used for? 
Za kaj se zdravilo Onduarp uporablja?
What is Onduarp? 
Kaj je zdravilo Onduarp?
How is Onduarp used? 
Kako se zdravilo Onduarp uporablja?
Under these circumstances vision loss may be rapid and severe. 
V takšnih okoliščinah je izgubljanje vida lahko hitro in hudo.
Distribution, biotransformation and elimination: 
Porazdelitev, biotransformacija in izločanje:
It is important to identify and treat these types of conditions as soon as possible. 
Zelo pomembno je, da takšna stanja čim prej prepoznamo in zdravimo.
These finding are therefore considered to be of limited clinical relevance. 
Zato velja, da so te ugotovitve omejenega kliničnega pomena.
Please do not forget to tell your doctor if you are known to be allergic to any substance. 
Ne pozabite obvestiti zdravnika, če veste, da ste alergični na katerokoli snov.
The following information is intended for healthcare professionals only: 
V nadaljevanju navedene informacije so namenjene le zdravstvenemu osebju:
Soon after the injection serious allergic reactions may occur. 
Kmalu po injiciranju se lahko pojavi resna alergijska reakcija.
At the end of the first year (week 54), 1053 patients were re-randomized to either continue or discontinue treatment through week 102. 
Na koncu prvega leta (54. teden) so približno 1.053 bolnikov ponovno randomizirali, bodisi na nadaljevanje zdravljenja ali na njegovo prekinitev do 102. tedna.
This will reduce or prevent any pain you might have with the injection. 
To bo zmanjšalo ali preprečilo kakršnokoli bolečino, ki bi se lahko pojavila med injiciranjem.
Frequency of these side effects cannot be estimated from the data available. 
Pogostnosti teh neželenih učinkov iz razpoložljivih podatkov ne moremo oceniti.
Investigations Uncommon increased gamma-glutamyltransferase activity 
Preiskave občasni zvišanje aktivnosti gama-glutamiltransferaze
The symptoms you might experience are described in section 2 of this leaflet ("Warnings and precautions"). 
Simptomi, ki se vam lahko pojavijo, so opisani v 2. poglavju tega navodila („Opozorila in previdnostni ukrepi“).
Your doctor will also give you some local anaesthetic (numbing medicine). 
Zdravnik vam bo dal tudi lokalni anestetik (sredstvo za omrtvičenje).
* Post-marketing experience; see “Description of selected adverse reactions” 
* Izkušnje v obdobju trženja zdravila; glejte „Opis izbranih neželenih učinkov“.
The symptoms you might experience and the instruction what to do in such cases are described in section 4 of this leaflet. 
Simptomi, ki se lahko pojavijo, in navodila, kaj storiti v takem primeru, so opisani v poglavju 4 tega navodila.
Data over a two-year period indicate that Macugen treatment should be initiated as early as possible. 
Podatki iz dveletnega obdobja kažejo, da je treba zdravljenje z zdravilom Macugen začeti čim prej.
MARKETING AUTHORISATION NUMBER(S) EU/1/05/325/002 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/05/325/002
Elderly No special considerations are needed. 
Posebna pazljivost ni potrebna.
If your doctor cannot be reached for any reason, an alternate doctor should be contacted immediately. 
Če zaradi kakršnegakoli razloga ne morete priti do svojega zdravnika, se morate nemudoma obrniti na drugega zdravnika.
Patients had up to one prior PDT and baseline visual acuity in the study eye between 20/40 and 20/320. 
Bolniki so imeli do eno predhodno PDT in izhodiščno ostrino vida na proučevanem očesu med 20/40 in 20/320.
Patients should be instructed not to drive or use machines until this has resolved. 
Bolnikom je treba naročiti, da ne smejo voziti ali upravljati strojev, dokler to ne mine.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY 
A. IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE
Date of latest renewal: 19/11/2015 
Datum prve odobritve: 31.1.2006 Datum zadnjega podaljšanja: 19.11.2015
Read all of this leaflet carefully before you start your treatment with this medicine because it contains important information for you. 
Pred začetkom zdravljenja natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
Children and adolescents Macugen should not be used in children and adolescents under 18 years old. 
Zdravila Macugen se ne sme uporabljati pri otrocih in mladostnikih, mlajših od 18 let.
The plunger stopper should not be pulled back. 
Gumijastega tesnila ne smete potegniti nazaj.
On average, the treatment benefit was maintained at 102 weeks with continuing preservation of visual acuity for patients re-randomized to continue pegaptanib. 
V povprečju se je korist zdravljenja ohranila do 102. tedna z nadaljnjo ohranitvijo ostrine vida pri bolnikih, ponovno randomiziranih na nadaljevanje zdravljenja s pegaptanibom.
The European Medicines Agency has waived the obligation to submit the results of studies with Macugen in all subsets of the paediatric population in age-related macular degeneration. 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Macugen pri vseh podskupinah pediatrične populacije s starostno degeneracijo makule.
Before the treatment is given your doctor may ask you to use antibiotic eye drops, or to wash your eyes carefully. 
Preden boste prejeli zdravilo, vam bo zdravnik morda naročil, da uporabite antibiotične kapljice za oko ali da si oči dobro umijete.
Store in a refrigerator (2ºC to 8ºC). 
Shranjujte v hladilniku (2-8 °C).
Your doctor will monitor your condition and recommend how long you should be treated with Macugen. 
Zdravnik bo spremljal vaše stanje in vam svetoval, kako dolgo naj traja zdravljenje z zdravilom Macugen.
• There is no experience of using Macugen in pregnant women. 
• Ni podatkov o uporabi zdravila Macugen pri nosečih ženskah.
Other possible side effects are as follows: 
Drugi možni neželeni učinki so:
Mean Change in VA from Week 0 (Letters) 
povprečna sprememba VA od tedna 0 (črke)
Pegaptanib pharmacokinetics is similar in female and male patients and within the age range 50 to 90 years. 
Farmakokinetika pegaptaniba je podobna pri bolnikih ženskega in moškega spola, starih od 50 let do 90 let.
Animal studies are insufficient, but have shown reproductive toxicity at high systemic exposure levels (see section 5.3). 
Študije na živalih niso bile zadostne, vendar so pokazale toksične učinke na sposobnost razmnoževanja pri veliki sistemski izpostavljenosti (glejte poglavje 5.3).
The odds of increased IOP was increased by a factor of 1.128 for each additional injection (p= 0.0003). 
Obeti za zvišan očesni tlak so se po vsakem dodatnem injiciranju povečali za faktor 1,128 (p = 0,0003).
The macula enables the eye to provide the fine central vision that is needed for activities such as driving a car, reading fine print and other similar tasks. 
Makula je del, s katerim oko omogoča podroben osrednji vid, potreben za dejavnosti, kakršne so vožnja avta, branje drobnega tiska in podobno.
Nevertheless, Macugen should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the foetus. 
Kljub temu je dovoljeno zdravilo Macugen med nosečnostjo uporabiti le, če možna korist za mater upravičuje potencialno tveganje za plod.
Treating physician should always expel excess volume of solution according to instructions under the section 6.6. 
Zdravnik mora vedno odstraniti odvečni volumen raztopine v skladu z navodili v poglavju 6.6.
What Macugen is and what it is used for 
Kaj je zdravilo Macugen in za kaj ga uporabljamo
At one year, pegaptanib 0.3 mg exhibited a statistically significant treatment benefit for the primary efficacy endpoint; proportion of patients losing less than 15 letters of visual acuity (prespecified pooled analysis, pegaptanib 0.3 mg 70% versus Sham 55%, p = 0.0001; EOP1003 pegaptanib 0.3 mg 73% versus Sham 59%, p = 0.0105; EOP1004 pegaptanib 0.3 mg 67% versus Sham 52%, p = 0.0031). 
Po enem letu je pegaptanib v odmerku 0,3 mg v obeh preskušanjih pokazal statistično pomembno korist zdravljenja, kar zadeva učinkovitost kot primarni opazovani dogodek, tj. delež bolnikov, ki se jim je ostrina vida zmanjšala za manj kot 15 črk (vnaprej določena kumulativna analiza, pegaptanib 0,3 mg 70 %, placebo 55 %, p = 0,0001; EOP1003 pegaptanib 0,3 mg 73 %, placebo 59 %, p = 0,0105; EOP1004 pegaptanib 0,3 mg 67 %, placebo 52 %, p = 0,0031).
What you need to know before you are given Macugen 
Kaj morate vedeti, preden boste prejeli zdravilo Macugen
A direct relationship to Macugen or any of the various treatments administered as part of the injection preparation procedure, or to other factors has not been established in these cases. 
Direktna povezava z zdravilom Macugen, drugimi zdravljenji, ki se uporabljajo pri postopku priprave na injiciranje, ali z drugimi faktorji v teh primerih ni bila dokazana.
Please read section 2. 
Preberite 2. poglavje.
A decrease in creatinine clearance down to 20 ml/min may be associated with up to a 2.3-fold increase in pegaptanib AUC. 
Zmanjšanje očistka kreatinina do 20 ml/min lahko spremlja do 2,3-kratno povečanje AUC pegaptaniba.
Other medicines and Macugen 
Druga zdravila in zdravilo Macugen
Caution should be exercised when treating such patients (see section 4.8, heading ‘Product-class-related adverse reactions'). 
Pri zdravljenju takih bolnikov je potrebna previdnost (glejte poglavje 4.8, pod naslovom „Na skupino zdravil vezani neželeni učinki“).
In mice, rats, rabbits, dogs and monkeys, pegaptanib distributes primarily into plasma volume and is not extensively distributed to peripheral tissues after intravenous administration. 
Pri miših, podganah, kuncih, psih in opicah se pegaptanib porazdeli predvsem v plazemski volumen in se po intravenski uporabi ne porazdeli izdatno v periferna tkiva.
• Macugen is not recommended during breastfeeding as it is not known whether Macugen passes into human milk. 
• Uporaba zdravila Macugen med dojenjem ni priporočljiva, ker ni znano, ali zdravilo Macugen prehaja v materino mleko.
If you are affected, do not drive or use machines until this resolves. 
Če se to zgodi, ne upravljajte vozil in strojev, dokler ne mine.
Summary of Mean Changes in Visual Acuity from Baseline to Weeks 6, 12, 54 and 102 (LOCF) EOP 1004 
Povzetek povprečne spremembe VA od začetka do tedna 6, 12, 54 in 102 (zadnje izvedeno opazovanje) EOP 1003
A total of 1190 patients were treated (892 pegaptanib, 298 sham (control)) with a median age of 77 years. 
Skupaj je bilo zdravljenih 1.190 bolnikov (892 jih je dobivalo zdravilo Macugen in 298 placebo (kontrolno snov)); mediana starost je bila 77 let.
Injury, poisoning and procedural complications 
Poškodbe in zastrupitve in zapleti pri posegih občasni
Reduced body weight (5%) and minimal delayed ossification in forepaw phalanges were observed, only at exposure levels based on AUC of over 300 fold greater than that expected in humans. 
Opažali so zmanjšanje telesne mase (5 %) in minimalno zamudo pri osifikaciji falang sprednjih tac, a le pri izpostavljenostih, ki so bile na podlagi AUC več kot 300-krat večje, kot so pričakovane pri človeku.
The safety and efficacy of Macugen beyond two years has not been demonstrated. 
Varnost in učinkovitost zdravila Macugen pri terapiji, daljši od dveh let, nista bili dokazani.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before Macugen treatment. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči, ali načrtujete zanositev, se pred zdravljenjem z zdravilom Macugen posvetujte z zdravnikom.
All injections of Macugen will be administered by your doctor. 
Vse injekcije zdravila Macugen vam bo dal zdravnik.
At this point, the remaining content of the syringe should be injected. 
Preostalo vsebino injekcijske brizge se sedaj lahko injicira.
After each injection you might be asked to use antibiotic eye drops (or another type of antibiotic treatment) to guard against eye infection. 
Po vsakem injiciranju vam bo zdravnik morda naročil, da za zaščito pred okužbo uporabite antibiotične kapljice za oko (ali kakšno drugo vrsto antibiotičnega zdravila).
The MAH shall ensure that, following discussions and agreement with the National Competent Authorities in each Member State where Macugen is marketed, at launch and after launch all ophthalmological clinics where Macugen is expected to be used are provided with an updated physician information pack containing the following elements: 
Imetnik dovoljenja za promet mora po razpravah in v dogovoru s pristojnimi nacionalnimi organi v vsaki državi članici, kjer se zdravilo Macugen trži, zagotoviti, da bodo ob in po prihodu zdravila na trg trg vse oftalmološke klinike, kjer se bo zdravilo Macugen predvidoma uporabljajo, prejele posodobljeno gradivo za zdravnike, ki vključuje naslednje elemente:
Moreover patients should be closely monitored for vitreous haemorrhage and endophthalmitis in the two weeks following the injection. 
Poleg tega je treba bolnike dva tedna po injekciji natančno nadzirati glede krvavitve v steklovino in endoftalmitisa.
Cases of serious allergic reaction, including anaphylactic reaction and angioedema of which symptoms are described below, has been reported soon after the injection. 
Poročali so o primerih resne alergične reakcije, vključno z anafilaktično reakcijo in angioedemom, katere simptomi so opisani spodaj in ki se je pojavila kmalu po injiciranju.
Macugen should not be used during pregnancy unless the potential benefit outweighs the potential risk to the unborn child. 
Zdravilo Macugen se med nosečnostjo ne sme uporabljati, razen če možna korist zdravljenja odtehta možno tveganje za še nerojenega otroka.
The safety and efficacy of Macugen in children under 18 years has not yet been established. 
Varnost in učinkovitost zdravila Macugen pri otrocih, mlajših od 18 let, še nista bili dokazani.
The majority of adverse reactions reported following administration of Macugen are related to the intravitreal injection procedure. 
Večina neželenih učinkov, o katerih so poročali po aplikaciji zdravila Macugen, je povezanih s postopkom intraviteralnega injiciranja.
Prior to launch in each Member State the Marketing Authorisation Holder (MAH) shall agree the final educational material with the National Competent Authority. 
Imetnik dovoljenja za promet mora pred prihodom zdravila na trg v vsaki državi članici s pristojnimi nacionalnimi organi dogovoriti končno izobraževalno gradivo.
Patients received a mean of between 8.4-8.6 treatments out of possible 9 total across all treatment arms in the first year. 
Bolniki v vseh krakih študije so v prvem letu dobili povprečno 8,4-8,6 odmerkov od skupno možnih 9.
The pouch must not be opened until the patient has been prepared for injection. 
Vrečke ne smete odpreti, dokler bolnik ni pripravljen za injiciranje.
(Actual air bubble formation may vary) 
(Dejanska prisotnost zračnih mehurčkov lahko variira.)
The two trials enrolled patients, including all neovascular AMD lesion subtypes (25% predominantly classic, 39% occult with no classic and 36% minimally classic), lesion sizes up to 12 disc areas, of which up to 50% could be comprised of subretinal haemorrhage and/or up to 25% fibrotic scar or atrophic damage. 
Preskušanji sta vključevali bolnike z vsemi podvrstami lezij neovaskularne AMD (25 % pretežno klasičnih, 39 % prikritih brez klasičnih in 36 % osnovnih klasičnih), velikostjo lezij do 12 površin diskusa, od katerih jih je bilo lahko do 50 % zapletenih s podmrežnično krvavitvijo in/ali do 25 % s fibrotičnim brazgotinjenjem ali atrofično okvaro.
This disease leads to vision loss resulting from damage to the central part of the retina (called the macula), at the back of the eye. 
Ta bolezen, ki povzroči izgubljanje vida, nastane zaradi okvare osrednjega dela mrežnice (imenujemo ga makula), ki leži na zadnji strani očesa.
Psychiatric disorders Uncommon nightmare, depression 
Psihiatrične motnje občasni nočna mora, depresija
Two early clinical studies conducted in patients who received Macugen alone and in combination with PDT (photodynamic therapy) revealed no apparent difference in the plasma pharmacokinetics of pegaptanib. 
Zgodnji klinični študiji pri bolnikih, ki so dobili zdravilo Macugen samo in v kombinaciji s fotodinamično terapijo, nista pokazali očitnih razlik v plazemski farmakokinetiki pegaptaniba.
To prevent contamination, the syringe should not be removed from the pouch until the patient has been prepared for injection. 
Da bi preprečili kontaminacijo, injekcijske brizge ne smete vzeti iz vrečke, dokler bolnik ni pripravljen na injiciranje.
The systemic exposure is expected to be within a well tolerated range in patients with hepatic impairment, as a 10 fold higher dose (3 mg/eye) was well tolerated. 
Po pričakovanju naj bi bila sistemska izpostavljenost pri bolnikih z okvaro jeter v območju, ki ga bolniki dobro prenesejo, saj so dobro prenašali do 10-krat večji odmerek (3 mg/oko).
Immune system disorders Not known anaphylactic reaction* 
Bolezni imunskega sistema neznana anafilaktična reakcija*
• palpitations, high blood pressure, dilatation of the aorta (the main blood vessel) 
• razbijanje srca, visok krvni tlak, razširitev aorte (glavne telesne krvne žile)
There are no studies on the carcinogenic potential of pegaptanib. 
Študij o kancerogenosti pegaptaniba ni.
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL 
POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
A post marketing observational study has also reported on a small risk of slow sustained increase in intraocular pressure (see section 4.8). 
V opazovalni študiji v obdobju trženja zdravila so prav tako poročali o majhnem tveganju za počasno ter vztrajno zvišanje očesnega tlaka (glejte poglavje 4.8).
The injection procedure should be carried out under aseptic conditions, which includes the use of surgical hand disinfection, sterile gloves, a sterile drape and a sterile eyelid speculum (or equivalent) and the availability of sterile paracentesis (if required). 
Postopek injiciranja moramo opraviti v aseptičnih pogojih, kar vključuje kirurško dezinfekcijo rok, uporabo sterilnih rokavic, sterilnega pokritja in sterilnega spekuluma za veke (ali drugega ustreznega instrumenta) ter dosegljivost sterilne paracenteze (če je potrebno).
It tells you what to do if you have any of these symptoms. 
V njem boste našli napotke za ravnanje v primeru, če se pojavi kateri izmed teh simptomov.
In animals that received doses of pegaptanib up to 0.5 mg/eye to both eyes, plasma concentrations were 0.03% to 0.15% of those in the vitreous humour. 
Pri živalih, ki so dobile pegaptanib v odmerkih do 0,5 mg/oko v obe očesi, je koncentracija v plazmi znašala 0,03-0,15 % tiste v steklovini.
Drug interaction studies have not been conducted with Macugen. 
Študij medsebojnega delovanja z zdravilom Macugen niso izvedli.
• elevation of the liver enzymes, abrasion. 
• zvišanje jetrnih encimov, abrazija
Cases of serious increase in intraocular pressure have been reported when the excess volume in the pre-filled syringe was not expelled before injection. 
Poročali so o primerih resnega zvišanja očesnega tlaka, kadar pred injiciranjem iz napolnjene injekcijske brizge ni bil odstranjen odvečni volumen.
For additional information regarding sodium content of Macugen, see section 
Za dodatne informacije o vsebnosti natrija v zdravilu Macugen glejte poglavje 2.
Patients who were re-randomized to discontinue pegaptanib after one year, lost visual acuity during the second year. 
Bolnikom, ki so bili ob ponovni randomizaciji po enem letu razvrščeni za prekinitev zdravljenja s pegaptanibom, se je ostrina vida v drugem letu zmanjšala.
Dose adjustments are not recommended in patients with mild or moderate renal impairment (see section 5.2). 
Prilagoditev odmerka pri bolnikih z blago ali zmerno okvaro ledvic ni priporočena (glejte poglavje 5.2).
In some patients the pressure inside the treated eye may increase for a short period directly after the injection. 
Pri nekaterih bolnikih se lahko za krajši čas neposredno po injiciranju zviša tlak v zdravljenem očesu.
Therefore, in case of overdose, intraocular pressure should be monitored and if deemed necessary by the treating physician, adequate treatment should be initiated. 
V primeru prevelikega odmerjanja je treba spremljati očesni tlak in uvesti primerno zdravljenje, če zdravnik presodi, da je to potrebno.
Pegaptanib sodium has not been adequately studied in patients with creatinine clearance below 20 ml/min. 
Natrijev pegaptanib ni ustrezno raziskan pri bolnikih z očistkom kreatinina pod 20 ml/min.
Read the package leaflet before use. 
Pred uporabo preberite navodilo!
Please tell your doctor immediately if you notice any of the following symptoms: eye pain or increased discomfort, worsening eye redness, blurred or decreased vision, increased sensitivity to light, increased number of small particles in your vision. 
Zdravniku morate takoj povedati, če opazite katerega od naslednjih simptomov: bolečino ali močnejše nelagodje v očesu, poslabšanje pordelosti oči, zamegljen ali poslabšan vid, večjo občutljivost za svetlobo, številnejše drobne delce v vidnem polju.
CAUTION: Since the pre-filled syringe contains more medicinal product volume (250-270 microlitres) than the recommended dose (90 microlitres), a part of the volume contained in the syringe has to be discarded prior to the administration. 
OPOZORILO: Ker napolnjena injekcijska brizga vsebuje večji volumen zdravila (250-270 mikrolitrov) od priporočenega odmerka (90 mikrolitrov), je treba del volumna v injekcijski brizgi zavreči pred aplikacijo zdravila.
The rate of absorption from the eye is the rate-limiting step in the disposition of pegaptanib in animals and is likely to be in humans. 
Hitrost absorpcije iz očesa je stopnja, ki omejuje hitrost izločanja pegaptaniba pri živalih; verjetno je tako tudi pri človeku.
- The active substance is pegaptanib. 
- Zdravilna učinkovina je pegaptanib.
Pegaptanib 0.3 mg showed treatment benefit regardless of baseline lesion subtype, lesion size and visual acuity as well as age, gender, iris pigmentation and prior and/or baseline PDT usage. 
Zdravljenje s pegaptanibom v odmerku 0,3 mg je koristilo ne glede na vrsto izhodiščne lezije, velikost lezije ali ostrino vida in prav tako ne glede na starost, spol, pigmentacijo šarenice ter predhodno in/ali izhodiščno PDT.
After 2 consecutive injections of Macugen, if a patient does not demonstrate a treatment benefit (loss of less than 15 letters of visual acuity) at the 12-week visit, consideration should be given to stopping or withholding Macugen therapy. 
Če pri bolniku po 2 zaporednih prejetih injekcijah zdravila Macugen na pregledu v 12. tednu ni opazne koristi zdravljenja (izguba ostrine vida za manj kot 15 črk), je treba razmisliti o prekinitvi ali začasni prekinitvi zdravljenja z zdravilom Macugen.
If the solution appears cloudy, particles are observed or if there is evidence of damage to the syringe, or if the plastic clip is missing or not attached to the syringe, that Macugen dose should not be used. 
Če je raztopina motna, so v njej vidni delci ali je injekcijska brizga poškodovana ali če plastičnega zatiča ni oziroma ni pritrjen na brizgo, tega odmerka zdravila Macugen ne smete uporabiti.
The medicine is used for the treatment of all types of abnormal blood vessels growth in adult AMD patients. 
Zdravilo uporabljamo za zdravljenje vseh vrst nenormalne rasti žil pri odraslih bolnikih z AMD.
N Mean change in VA Week 
N Povprečna sprememba VA v tednu
OTHER SPECIAL WARNING(S), IF NECESSARY CAUTION: Expel excess volume before injecting. 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA OPOZORILO: Pred injiciranjem odstranite odvečni volumen.
The mean area under the plasma concentration-time curve (AUC) is about 25 g·hr/ml at this dose. 
Ob tem odmerku je povprečna površina pod krivuljo plazemske koncentracije po času (AUC) približno 25 g∙h/ml.
VEGF165 is the VEGF isoform preferentially involved in pathological ocular neovascularisation. 
VEGF165 je izooblika VEGF, ki je vpletena predvsem v patološko neovaskularizacijo v očesu.
Pharmacotherapeutic group: Ophthalmologicals, Ocular vascular disorder agents, ATC Code S01LA03. 
Farmakoterapevtska skupina: zdravila za zdravljenje očesno žilnih bolezni, oznaka ATC: S01LA03